Fig. 4: Identification of proteins and transcripts in enriched tumor cell populations associated with homologous recombination deficiency in high-grade serous ovarian cancer. | npj Precision Oncology

Fig. 4: Identification of proteins and transcripts in enriched tumor cell populations associated with homologous recombination deficiency in high-grade serous ovarian cancer.

From: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

Fig. 4

a Integration of germline and somatic mutation status for breast cancer type 1 and 2 susceptibility protein (BRCA1/2), and classification of tumors as homologous recombination deficient (HRD) or proficient (HRP) by probability of HRD (continuous) by CHORD score and scarHRD. b Top pathways enriched among proteins significantly altered (LIMMA p-value < 0.01) between patient tumors classified as HRD or HRP; default settings in metascape.org. c Differential analysis of enriched tumor cell proteome (left panel) and transcript (right panel) data from HRD (n = 18) vs HRP (n = 51) patients (LIMMA, adjusted p < 0.05). d Correlation analysis of 54 HRD-associated transcripts with an independent cohort of HGSOC patients classified as HRD (n = 69) or HRP (n = 57) by CHORD score (R = Spearman Rho). e Classification of HRD (n = 69) vs HRP (n = 57) tumors using an integrated 54 protein/transcript HRD expression signature in an independent cohort of HGSOC patients (receiver operating characteristic curve, AUC = 0.81, p < 1E−9).

Back to article page